Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process TA
ID number 6262

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield


Companies sponsors Pfizer (nirmatrelvir and ritonavir)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Action for Pulmonary Fibrosis
  Anthony Nolan
  Blood Cancer UK
  British Society for Heart Failure
  Cardiothoracic Transplant Patient Group
  Clinically Vulnerable Families
  Crohn’s & Colitis UK
  Diabetes UK
  Down’s Syndrome Association
  Immunodeficiency UK
  Kidney Care UK
  Kidney Research UK
  Leukaemia Care
  Long Covid Kids
  Long Covid Support
  Lymphoma Action
  MS Society
  Multiple Sclerosis Trust
  Myeloma UK
  Sarcoidosis UK
  Thrombosis UK
Professional groups Association of Cancer Physicians
  British Infection Association
  British Paediatric Allergy Infection and Immunity Group
  British Society for Allergy & Clinical Immunology
  British Society for Immunology
  British Thoracic Society
  British Transplantation Society
  Cancer Research UK
  Faculty of Pharmaceutical Medicine
  Royal College of Physicians
  UK Clinical Pharmacy Association
  UK Kidney Association
  UK Renal Pharmacy Group
Associated public health groups UK Health Security Agency
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Long Covid Research Initiative


Key events during the development of the guidance:

Date Update
11 January 2024 - 25 January 2024 Final draft guidance: 2
01 November 2023 Consultation documents published: Funding Variation consultation
15 September 2023 Following the publication of the final draft guidance for this topic, NICE has received a request from NHS England to vary the funding requirement in section 4 of the guidance. When NICE receives a request to vary the funding requirement it is considered by NICE’s Guidance Executive. If NICE’s Guidance Executive decides to accept the request, this decision will be shared with stakeholders for a 21-day consultation. Comments received during consultation from stakeholders will be presented to Guidance Executive to reach a final decision on the timescale for the funding requirement. If the final decision is to vary the funding timescale, this will be reflected in updated final draft guidance which will be reissued for an appeal period.
17 August 2023 - 24 August 2023 Final draft guidance
13 June 2023 Committee meeting: 2
04 May 2023 - 25 May 2023 Draft guidance
04 April 2023 Committee meeting: 1
20 February 2023 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual